First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study - Necchi, A; Lo, Vullo S; Perrone, F (BJU Int, 2018)
et al.